SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Seagate entered into exchange agreements to convert $185.908 million principal amount of exchangeable notes into cash and ordinary shares issued pursuant to Section 4(a)(2) exemption from registration. The transaction materially affects the company's capital structure and results in dilution to existing shareholders through the issuance of unregistered equity securities.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from River Financial Corp's 2026 Annual Meeting of Stockholders held on May 19, 2026. The filing presents the election of nine director nominees with detailed vote tallies (Votes For, Against, Abstain, and Broker non-votes) for each candidate, which is the quintessential content of Item 5.07 shareholder vote results disclosures. Director elections are material governance events affecting investor assessment of board composition and control.
View raw filing on EDGAR →The filing explicitly states that Urban Outfitters issued an earnings release on May 20, 2026, disclosing "material non-public information regarding the Company's earnings for the three months ended April 30, 2026." This is a direct disclosure of quarterly financial results, which is the core definition of an earnings_release event. The characterization as "material non-public information" and the attachment of the earnings release as Exhibit 99.1 confirm this classification.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Phathom Pharmaceuticals' 2026 Annual Meeting held on May 19, 2026. The filing presents final voting tallies for three proposals: election of Class I directors (Steven Basta, Theodore R. Schroeder, Mark Stenhouse), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. This is a routine but material Item 5.07 disclosure required by SEC rules.
View raw filing on EDGAR →Chart Industries disclosed a material acquisition by Baker Hughes under Item 8.01 (Other Events). The filing reports that on July 28, 2025, Chart entered into an Agreement and Plan of Merger with Baker Hughes, whereby Chart will be acquired and survive as an indirect wholly owned subsidiary of Baker Hughes. The disclosure further notes that Baker Hughes filed a Form CO with the European Commission on May 21, 2026, initiating Phase I regulatory review, with expected closing in July 2026. This constitutes a material M&A transaction requiring disclosure under Item 1.01 or analogous provisions, though reported here under Item 8.01 as a regulatory milestone update.
View raw filing on EDGAR →Research Alliance Corp III consummated its IPO on May 21, 2026, entering into material definitive agreements including an Underwriting Agreement, Investment Management Trust Agreement, and Private Placement Shares Purchase Agreement, raising $75 million in gross IPO proceeds and establishing the company's framework for future business combinations.
View raw filing on EDGAR →The Sponsor purchased 275,000 Class A ordinary shares at $10.00 per share for $2.75 million in proceeds pursuant to Section 4(a)(2) of the Securities Act, representing an unregistered private placement concurrent with the IPO.
View raw filing on EDGAR →Michael F. MacLean and Timothy J. Miller were appointed to the Board of Directors effective May 19, 2026, in connection with the Company's IPO, with concurrent appointments to the Audit, Nominating, and Compensation committees.
View raw filing on EDGAR →The company adopted an Amended and Restated Memorandum and Articles of Association in connection with its IPO on May 19, 2026, establishing the company's post-IPO governance structure and shareholder rights.
View raw filing on EDGAR →Baker Hughes discloses a material acquisition of Chart Industries pursuant to a Merger Agreement dated July 28, 2025. The filing reports progress toward closing: completion of pre-notification with the European Commission and filing of a Form CO on May 21, 2026, initiating Phase I regulatory review. The company expects the merger to close in July 2026, subject to regulatory approvals and customary closing conditions. This is a significant M&A transaction requiring SEC disclosure under Item 8.01.
View raw filing on EDGAR →Lukas Biewald was appointed to the Board of Directors effective May 20, 2026, and concurrently appointed to the Nominating and Corporate Governance Committee. The appointment includes compensatory arrangements consisting of RSU awards and cash retainers.
View raw filing on EDGAR →Lumen Technologies' subsidiary Level 3 Financing completed a $1.0 billion offering of senior notes and entered into an indenture on May 21, 2026. The transaction includes change-of-control provisions, restrictive covenants, and guarantees from the parent and material subsidiaries, with proceeds used to fund concurrent tender offers.
View raw filing on EDGAR →Flowers Foods disclosed financial results for the 16-week period ended April 25, 2026, via press release filed under Item 2.02.
View raw filing on EDGAR →The company reset its dividend policy, reducing the annual dividend rate to $0.50 per share and declaring a quarterly dividend of $0.1250 per share, representing a significant change to shareholder return policy.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the results of Hyperfine's 2026 annual meeting of stockholders held on May 21, 2026, including the reelection of five board directors (Daniel J. Wolterman, Maria Sainz, John Dahldorf, Ruth Fattori, and Jonathan M. Rothberg, Ph.D.) and the ratification of Grant Thornton LLP as independent auditor, with detailed vote tallies for each proposal. The disclosure of shareholder meeting results is a material governance event that affects investor understanding of board composition and audit oversight.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from BrightSpring's 2026 Annual Meeting of Stockholders held on May 21, 2026. The filing reports the outcomes of three proposals: election of three Class II directors (Olivia Kirtley, Max Lin, and Steve Miller), ratification of KPMG LLP as independent auditor, and an advisory vote on executive compensation. All three items were approved. This is a material event as it reflects shareholder approval of board composition and auditor selection, which are fundamental governance matters affecting investor confidence.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of TransMedics' 2026 Annual Meeting of Shareholders held on May 20, 2026, including voting outcomes on four proposals: election of eight directors, advisory approval of named executive officer compensation, amendment to the 2019 Stock Incentive Plan, and ratification of PricewaterhouseCoopers LLP as independent auditor. The detailed vote tallies for each proposal are material to shareholders' understanding of governance and corporate direction.
View raw filing on EDGAR →Shareholders voted at the Annual Meeting held on May 20, 2026, approving the election of eleven directors, an advisory vote on named executive officer compensation, an amendment and restatement of the Employee Stock Purchase Plan increasing authorized shares from 100,000 to 400,000, and the ratification of Deloitte & Touche LLP as independent auditor.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from TPG RE Finance Trust's 2026 Annual Meeting of Stockholders held on May 19, 2026. The filing reports voting outcomes for three proposals: election of eight directors, ratification of Deloitte & Touche LLP as independent auditor, and an advisory vote on executive compensation. The detailed vote tallies (For, Against, Withheld, Abstentions, and Broker Non-Votes) for each proposal are the hallmark of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →The filing discloses Copart's financial results for the third quarter of fiscal year 2026 (ended April 30, 2026) via a press release issued on May 21, 2026 and furnished as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02, which would materially affect a reasonable investor's assessment of the company's operational and financial performance.
View raw filing on EDGAR →GATX Corporation amended its Five Year Credit Agreement on May 21, 2026, extending the termination date by one year to May 21, 2031 and reducing borrowing margins and facility fees. This material refinancing/restructuring of existing debt terms does not constitute an acquisition, disposition, or change of control.
View raw filing on EDGAR →Victory Capital entered into a Seventh Amendment to its Credit Agreement on May 18, 2026, refinancing existing term loans with repriced term loans at lower interest rates (SOFR plus 1.75% or alternate base rate plus 0.75%), materially affecting the company's debt structure and cost of capital.
View raw filing on EDGAR →Alphabet closed a ¥576.9 billion (~$3.8 billion USD equivalent) underwritten public offering of Japanese yen-denominated senior notes across seven tranches with maturities from 2029 to 2066. While this is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, it does not fit cleanly into the standard M&A, dilutive equity issuance, or other specific event categories—it is a debt financing activity disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →ClearPoint Neuro held its Annual Meeting of stockholders and disclosed voting results for four proposals: election of seven directors, ratification of Cherry Bekaert LLP as auditors, advisory approval of executive compensation, and approval of the Seventh Amended and Restated 2013 Incentive Compensation Plan. All proposals were approved by shareholders.
View raw filing on EDGAR →Third Coast Bancshares held its Annual Meeting of Shareholders on May 21, 2026, with voting results on three matters: election of directors to Classes A and C, approval of the Restated Omnibus Incentive Plan (increasing share reserves by 375,000 shares and modifying equity award terms), and ratification of Whitley Penn LLP as independent auditor.
View raw filing on EDGAR →While the section discloses both an executive departure (William R. Devlin retiring as Chief Accounting Officer effective June 1, 2026) and an appointment (Samuel M. Guzman Jr. becoming Senior Vice President, Chief Accounting Officer and Controller), the bulk of the Item 5.02 disclosure centers on Item 5.02(e) compensatory arrangements. The Compensation Committee approved three incentive compensation programs (Eagle Plan, Business Unit Plan, and Special Situation Program) with specific bonus pools, performance metrics, and maximum bonus potentials for named executive officers. The compensation disclosure is more extensive and material than the succession narrative, making exec_compensation the most salient classification.
View raw filing on EDGAR →Amit Muni was appointed as Executive Vice President and Chief Financial Officer effective June 8, 2026, succeeding Michael Donohue. The appointment includes compensatory terms including a base salary of $450,000, guaranteed bonuses, and RSU awards.
View raw filing on EDGAR →Hub Group received a notice from Nasdaq on May 19, 2026 that it failed to comply with Listing Rule 5250(c)(1) by not timely filing its Q1 2026 Form 10-Q. The company has been granted until June 3, 2026 to submit a compliance plan and until September 14, 2026 to file delinquent reports, with potential delisting if compliance is not regained within the prescribed timeframe.
View raw filing on EDGAR →Charles Schwab issued $2.25 billion in aggregate principal amount of senior notes ($1 billion at 4.744% due 2030 and $1.25 billion at 5.493% due 2037) with net proceeds of approximately $2.236 million. This is a material debt issuance that does not fit the dilutive_issuance category (which applies to equity securities) and is not a covenant breach, restatement, or other more specific event type. The disclosure of a substantial debt offering is material to investors assessing the registrant's capital structure and financial position.
View raw filing on EDGAR →Onto Innovation issued $1.7 billion in aggregate principal amount of 0.00% Convertible Senior Notes due 2031, convertible into common stock at an initial conversion price of approximately $381.80 per share, with net proceeds of approximately $205 million used to repurchase 805,325 shares. The convertible notes represent a significant dilutive capital raise with substantial equity component and conversion potential affecting shareholder equity.
View raw filing on EDGAR →Kraft Heinz issued €1 billion in aggregate principal amount of senior notes on May 21, 2026, pursuant to a shelf registration statement, with proceeds earmarked for a concurrent tender offer to repurchase outstanding senior notes due 2046 and 2049. This debt refinancing activity—combining new issuance with debt repurchase—constitutes a material capital structure transaction affecting the company's financial position and leverage profile.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Bruker Corporation's 2026 Annual Meeting of Stockholders held on May 21, 2026. The filing reports final vote tallies for three proposals: election of Class II directors (Laura A. Francis, John J. Phillips, Hermann F. Requardt), advisory approval of 2025 named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. This is a quintessential Item 5.07 disclosure of shareholder voting outcomes, which is material to investors as it reflects governance decisions and stakeholder approval of key corporate matters.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Verisk Analytics' 2026 Annual Meeting held on May 19, 2026. The filing presents detailed voting tallies for four proposals: election of eleven board directors, say-on-pay advisory vote, auditor ratification, and a shareholder proposal on written consent rights. The comprehensive vote counts and named director nominees are unmistakable indicators of shareholder meeting results.
View raw filing on EDGAR →EagleRock Land assumed a $263.3 million Predecessor Credit Facility (maturing July 3, 2027) and entered into a new $200 million revolving Credit Facility with JPMorgan Chase in connection with its IPO closing, materially altering the company's capital structure and leverage position.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Willis Towers Watson's 2026 Annual General Meeting held on May 20, 2026, including voting outcomes on director elections, auditor ratification, executive compensation approval, share issuance authorities, and employee share plan amendments. The filing presents detailed vote tallies for each proposal, which is the core content of shareholder vote results disclosures required under Item 5.07.
View raw filing on EDGAR →Choice Hotels held its Annual Meeting of Shareholders on May 21, 2026, with shareholders voting on four proposals: election of eleven directors, advisory vote on executive compensation, amendment to the Certificate of Incorporation to expand the Board size range from 3-12 to 5-15 directors, and ratification of Ernst & Young LLP as independent auditor. All four proposals passed with substantial majorities.
View raw filing on EDGAR →LSB Industries announced on May 18, 2026 that it will assume full ownership of a carbon capture and sequestration project from Lapis Carbon Solutions, with total consideration and remaining capital estimated at approximately $95 million. This constitutes a material acquisition or change of control of the Project, meeting the threshold for ma_activity disclosure under Item 8.01 (Other Events), with contingent consideration tied to milestone achievement.
View raw filing on EDGAR →This Item 5.07 filing discloses the final voting results from LSB Industries' 2026 annual meeting of stockholders held on May 21, 2026. The section presents detailed vote tallies for three matters: election of three director nominees (Jonathan Z. Ackerman, Diana M. Peninger, and Lynn F. White), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, and the directors were duly elected to serve until 2029.
View raw filing on EDGAR →FMC announced the pricing of a $1.2 billion offering of Senior Secured Notes due 2031. While this is a material debt issuance that would affect investor assessment of the company's capital structure and financial position, it does not fit cleanly into the taxonomy's more specific categories (ma_activity applies to acquisitions/dispositions/mergers, not debt offerings; dilutive_issuance applies to equity securities). The disclosure is material but best classified as other_material given the debt financing nature.
View raw filing on EDGAR →Hims & Hers issued $402.5 million in convertible notes on May 21, 2026, to qualified institutional buyers under Rule 144A, with up to 18,057,397 shares of Class A common stock potentially issuable upon conversion at an initial conversion price of $29.53 per share. This private placement of convertible securities represents a material dilutive issuance that will result in equity dilution to existing shareholders upon conversion.
View raw filing on EDGAR →Olema Pharmaceuticals announced preliminary Phase 1 clinical data for OP-3136, a KAT6 inhibitor, demonstrating favorable safety, tolerability, and early efficacy signals including tumor shrinkage in 13 of 19 patients and 3 partial responses with no dose-limiting toxicities. This clinical progress is material to investors' assessment of the company's pipeline and development prospects.
View raw filing on EDGAR →The Company disclosed receipt of a Nasdaq notice on March 17, 2026 that it had failed to maintain the minimum market value of listed securities ($50 million) required under Nasdaq Listing Rule 5450(b)(2)(A). Although the Company subsequently regained compliance by May 20, 2026 based on stockholders' equity meeting Rule 5450(b)(1)(A), the disclosure centers on a delisting risk event—the failure to satisfy a continued listing rule and the subsequent resolution. This is material to investors as it directly affects the Company's ability to remain listed on Nasdaq.
View raw filing on EDGAR →Relay Therapeutics entered into an Underwriting Agreement on May 20, 2026, for an underwritten public offering of 22,916,667 shares at $12.00 per share, with underwriters exercising a full 30-day option for an additional 3,437,500 shares, generating approximately $296.8 million in net proceeds. This is a material registered equity issuance that dilutes existing shareholders and materially affects the company's capital structure and investor assessment.
View raw filing on EDGAR →This disclosure announces an upcoming stockholder vote on the conversion of Series B Preferred Stock that would trigger a change of control under Nasdaq rules (>20% dilution and control change per Rules 5635(a) and 5635(b)). However, the filing is pre-meeting notice rather than post-meeting results. The material substance is the announced change-of-control transaction requiring shareholder approval, which more closely aligns with ma_activity (change of control), though the Item 8.01 placement and focus on the voting mechanics creates ambiguity about the intended classification.
View raw filing on EDGAR →The disclosure announces an option agreement with Hangzhou DAC Biotechnology providing access to a linker-payload (CPT113) for up to five additional ADC programs, which expands the Company's pipeline. While this represents a material strategic development for a biotech company's product pipeline, it does not fit cleanly into the more specific event categories (not an M&A transaction, not an earnings release, not an executive change, and not a financial impairment or covenant breach). The pipeline expansion through a licensing/option agreement is material to investors assessing the company's future prospects but is best classified as other_material.
View raw filing on EDGAR →This Item 8.01 disclosure centers on supplemental disclosures related to a previously announced merger agreement between FONAR Corporation and entities controlled by CEO Timothy Damadian. The filing updates the Definitive Proxy Statement and Schedule 13E-3/A filed on April 16, 2026, in connection with a special stockholder meeting scheduled for May 28, 2026, to vote on the proposed merger. While the Item is technically "Other Events," the substance is material M&A activity—specifically, supplemental disclosures addressing stockholder litigation allegations regarding disclosure deficiencies in the merger proxy materials. The company voluntarily supplemented disclosures to avoid litigation risks and allow stockholders to vote on the merger.
View raw filing on EDGAR →Veritone entered into an at-the-market (ATM) equity offering agreement with three sales agents authorizing the sale of up to $50 million in common stock shares. This is a registered dilutive issuance under Rule 415(a)(4) that would materially affect existing shareholders through potential equity dilution and is a significant capital-raising activity for the company.
View raw filing on EDGAR →The filing discloses the appointment of Michael Weinbach as CEO-Elect effective June 1, 2026, and subsequently as Chief Executive Officer and Board member effective August 13, 2026, succeeding retiring CEO Richard G. Thornberry. While the section also covers compensatory arrangements (base salary of $1,000,000, STI target of $1,166,666, and LTI awards totaling $6,000,000 plus sign-on equity), the principal disclosed action is Weinbach's appointment to the CEO role and the Board, making this an executive appointment event.
View raw filing on EDGAR →Kohl's Corporation held its Annual Meeting of Shareholders on May 20, 2026, with voting results on four proposals: election of eight directors, advisory vote on named executive officer compensation, ratification of Ernst & Young LLP as independent auditor, and approval of the amended 2024 Long-Term Compensation Plan.
View raw filing on EDGAR →Shareholders voted on and approved amendments to the Company's Certificate of Formation and Bylaws, including removal of references to SoftBank and a terminated Governance Agreement, and addition of an election under Texas Business Organizations Code Section 21.419.
View raw filing on EDGAR →